Marubeni Corporation has agreed to acquire a 60% stake in a new company formed to manage Sumitomo Pharma's pharmaceutical sales business across Asia for approximately 45 billion yen.

Information on the Target

Marubeni Corporation has finalized a Share Purchase Agreement with Sumitomo Pharma Co., Ltd. to acquire a 60% stake in a newly established entity that will inherit Sumitomo Pharma's pharmaceutical sales business across Asia. This transaction entails an investment of approximately 45 billion yen and involves the streamlined absorption of the existing sales operations conducted by Sumitomo Pharma's subsidiaries in the region.

The new company will operate primarily in China, Taiwan, Hong Kong, and various Southeast Asian nations, leveraging the reputation and network that Sumitomo Pharma has nurtured to enhance the distribution of essential medicinal products to local communities.

Industry Overview in Asia

The pharmaceutical sector in Asia possesses a robust growth trajectory, driven by factors such as population expansion, aging demographics, and significant economic development. As